Zobrazeno 1 - 10
of 223
pro vyhledávání: '"Jeffrey G. Supko"'
Autor:
Laura M. Spring, Shealagh L. Clark, Tianyu Li, Shom Goel, Nabihah Tayob, Elene Viscosi, Elizabeth Abraham, Dejan Juric, Steven J. Isakoff, Erica Mayer, Beverly Moy, Jeffrey G. Supko, Sara M. Tolaney, Aditya Bardia
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Preclinical evidence suggests synergy b
Externí odkaz:
https://doaj.org/article/33e1b363efc046cc98162a97b34fb552
Autor:
Nathan McDannold, Yongzhi Zhang, Jeffrey G. Supko, Chanikarn Power, Tao Sun, Natalia Vykhodtseva, Alexandra J. Golby, David A. Reardon
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-19 (2020)
Abstract We investigated controlled blood-brain barrier (BBB) disruption using a low-frequency clinical transcranial MRI-guided focused ultrasound (TcMRgFUS) device and evaluated enhanced delivery of irinotecan chemotherapy to the brain and a rat gli
Externí odkaz:
https://doaj.org/article/dbbc08312ca148409c6d22571344c92a
Autor:
Kristie A. Blum, Jeffrey G. Supko, Michael B. Maris, Ian W. Flinn, Andre Goy, Anas Younes, Suresh Bobba, Adrian M. Senderowicz, Sergey Efuni, Ronda Rippley, Gozde Colak, Patrick Trojer, Jeremy S. Abramson
Publikováno v:
Cancer Research Communications. 2:795-805
Purpose: NF-κB, a transcription factor essential for inflammatory responses, is constitutively activated in many lymphomas. In preclinical studies, pelabresib (CPI-0610), an investigational (BET) bromodomain inhibitor, downregulated NF-κB signaling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b03b5d50a187ff96ab01370d0ad3a0e
https://doi.org/10.1158/2767-9764.crc-22-0060
https://doi.org/10.1158/2767-9764.crc-22-0060
Autor:
Jeremy S. Abramson, Patrick Trojer, Gozde Colak, Ronda Rippley, Sergey Efuni, Adrian M. Senderowicz, Suresh Bobba, Anas Younes, Andre Goy, Ian W. Flinn, Michael B. Maris, Jeffrey G. Supko, Kristie A. Blum
Supplemental tables with the number of patients treated with number of cycles and the incidence of DLTs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3176bc8262bc52b8823efce4e47f6acd
https://doi.org/10.1158/2767-9764.22544999
https://doi.org/10.1158/2767-9764.22544999
Autor:
Jeremy S. Abramson, Patrick Trojer, Gozde Colak, Ronda Rippley, Sergey Efuni, Adrian M. Senderowicz, Suresh Bobba, Anas Younes, Andre Goy, Ian W. Flinn, Michael B. Maris, Jeffrey G. Supko, Kristie A. Blum
Purpose:NF-κB, a transcription factor essential for inflammatory responses, is constitutively activated in many lymphomas. In preclinical studies, pelabresib (CPI-0610), an investigational (BET) bromodomain inhibitor, downregulated NF-κB signaling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19ca73113538578549d12f5fbd38f10c
https://doi.org/10.1158/2767-9764.c.6550823
https://doi.org/10.1158/2767-9764.c.6550823
Autor:
Jeremy S. Abramson, Patrick Trojer, Gozde Colak, Ronda Rippley, Sergey Efuni, Adrian M. Senderowicz, Suresh Bobba, Anas Younes, Andre Goy, Ian W. Flinn, Michael B. Maris, Jeffrey G. Supko, Kristie A. Blum
CONSORT diagram of patient disposition throughout study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e50340fb0c681ba5dcfe11908415005
https://doi.org/10.1158/2767-9764.22545008.v1
https://doi.org/10.1158/2767-9764.22545008.v1
Autor:
Jonathan E. Rosenberg, Levi A. Garraway, Philip W. Kantoff, Stacey B. Gabriel, Eric S. Lander, David M. Sabatini, Geoffrey I. Shapiro, Massimo Loda, Sabina Signoretti, Edward C. Stack, Mary Ellen Taplin, Aymen A. Elfiky, James M. Cleary, Leena Gandhi, Toni K. Choueiri, Michelle Stewart, Jeffrey G. Supko, Susanna Jacobus, Eran Hodis, Eliezer M. Van Allen, Brian C. Grabiner, Nikhil Wagle
XLSX file 451K, Somatic mutations identified by whole exome sequencing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82d74b478dd036d9c182836ded6cdfd8
https://doi.org/10.1158/2159-8290.22530206
https://doi.org/10.1158/2159-8290.22530206
Autor:
Jonathan E. Rosenberg, Levi A. Garraway, Philip W. Kantoff, Stacey B. Gabriel, Eric S. Lander, David M. Sabatini, Geoffrey I. Shapiro, Massimo Loda, Sabina Signoretti, Edward C. Stack, Mary Ellen Taplin, Aymen A. Elfiky, James M. Cleary, Leena Gandhi, Toni K. Choueiri, Michelle Stewart, Jeffrey G. Supko, Susanna Jacobus, Eran Hodis, Eliezer M. Van Allen, Brian C. Grabiner, Nikhil Wagle
PDF file 196K, The Data Supplement contains Supplementary Tables 1-3, which provide additional detail about the clinical trial as well as Supplementary Methods and References
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cddc4dab1e3241ac279ae4aabe758092
https://doi.org/10.1158/2159-8290.22530212.v1
https://doi.org/10.1158/2159-8290.22530212.v1
Autor:
Jonathan E. Rosenberg, Levi A. Garraway, Philip W. Kantoff, Stacey B. Gabriel, Eric S. Lander, David M. Sabatini, Geoffrey I. Shapiro, Massimo Loda, Sabina Signoretti, Edward C. Stack, Mary Ellen Taplin, Aymen A. Elfiky, James M. Cleary, Leena Gandhi, Toni K. Choueiri, Michelle Stewart, Jeffrey G. Supko, Susanna Jacobus, Eran Hodis, Eliezer M. Van Allen, Brian C. Grabiner, Nikhil Wagle
PDF file 249K, Effect of pazopanib on S6K1 phosphorylation in cells expressing activating MTOR mutations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::374b71c5a825db756851f01dbe8284fe
https://doi.org/10.1158/2159-8290.22530209.v1
https://doi.org/10.1158/2159-8290.22530209.v1
Autor:
Seth A. Wander, Douglas S. Micalizzi, Taronish Dubash, Dejan Juric, Laura M. Spring, Neelima Vidula, Jennifer Keenan, Maureen Beeler, Elene Viscosi, Dante Che, Elizabeth L. Fisher, Rachel A. Hepp, Beverly Moy, Steven J. Isakoff, Leif W. Ellisen, Jeffrey G. Supko, Shyamala Maheswaran, Daniel A. Haber, Aditya Bardia
Publikováno v:
Cancer Research. 82:P1-18
Background: The cyclin-dependent kinase 4/6 inhibitors, with endocrine therapy (ET), have become the standard of care for patients with HR+/HER2- MBC. Prior insight from tumor biopsies and preclinical analyses suggest that AKT1 activation can provoke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb457a07f41242168c02a708d82b0d59
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-22
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-22